A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Updated Research Agenda For The Programmatic Management Of Drug-Resistant Tuberculosis
On May 25, PLoS One published an article by Dr. Carole Mitnick et al. on the updated research agenda for the programmatic management of drug-resistant tuberculosis (PMDT). The authors built upon previous PMDT publications by reviewing resources including guidelines, documents, websites and publications published between January 2008 and August 2013 that cited the last research agenda released in 2008. Resources reviewed spanned five main research categories: Laboratory Support, Epidemiology, Programmatically Relevant Research, Treatment Strategy, and Management of Contacts. Results showed that there was continuity around the priorities for research in PMDT that could help fill longstanding evidence gaps barring expanded treatment access. Identified priorities specifically highlighted the importance of increased coordinated efforts to address questions regarding: shorter treatment regimens; knowledge of disease burden without representative data; and treatment for latent TB infection in household contacts of known drug-resistant (DR-TB) patients. Addressing such questions is essential to stem the epidemic of TB, including DR-TB.
Read the open-access article here.
Recent News and Announcements
Mark your calendar for a presentation from Dr. Greg Fox on the V-QUIN MDR Trial taking place on Thursday, November 3rd at 08:00 EST (14:00 CET). The V-QUIN Trial is a randomized controlled trial that aims to evaluate six months of daily levofloxacin versus six months of placebo as preventative therapy among household contacts of […]
Akonni Biosystems is developing a simple, inexpensive device to isolate and purify Mycobacterium tuberculosis DNA from sputum. This device is not a test for tuberculosis; however, it could be paired with a separate molecular test (e.g. DNA amplification test including PCR, isothermal amplification, or sequencing) conducted on-site or at a central laboratory (stable without cold […]
RESIST-TB is excited to announce the creation of the Drug-Resistant Tuberculosis Working Group (DR-TB WG); the first meeting of this WG will take place during the Union Meeting, at 14:45-15:45 on Wednesday, October 26, 2016. This WG will gather and share information to help accelerate scale-up of evidence-based DR-TB policy and practice. The WG will address a series of […]
The development of Target Product Profiles for TB drug regimens (referred as Target Regimen Profiles – TRPs) intends to assist drug regimen developers towards important features and align these with patient and programmatic needs at country level. Link to publication
The World Health Organization (WHO) announced new recommendations for a shortened treatment regimen for multi-drug resistant tuberculosis (MDR-TB) patients – nine months compared to the current 24-month treatment standard used worldwide. Shorter regimen for patients At less than US$ 1000 per patient, the new treatment regimen can be completed in 9–12 months. The shorter regimen […]